Churg-Strauss Syndrome

This is a rare condition that affects the blood vessels. It causes inflammation in the blood vessels throughout the body, which can lead to serious problems like lung damage and heart issues. It often starts with asthma or a respiratory infection.

Condition

What people with Churg-Strauss Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you tried Prednisone for Churg-Strauss Syndrome?

NameHow it went

About Churg-Strauss Syndrome

What It Is

Churg-Strauss syndrome, now officially called eosinophilic granulomatosis with polyangiitis (EGPA), is a rare disease in which the immune system inflames small blood vessels (vasculitis) and drives a buildup of eosinophils, a type of white blood cell normally involved in allergic reactions. When eosinophils and inflamed vessels affect organs, they can damage the lungs, sinuses, nerves, skin, heart, gut and sometimes the kidneys. Almost everyone with the condition has asthma, often starting in adulthood and becoming hard to control, and many also have chronic sinus inflammation with nasal polyps. These airway problems can come years before anything else. Later signs may include fever, weight loss, fatigue, muscle and joint aches, a rash or purple spots on the skin, abdominal pain, and numbness, tingling or weakness in a hand or foot. Because it can damage the heart and nerves, recognizing it early matters: prompt treatment can prevent lasting organ damage.

Causes & Risk Factors

The cause of EGPA is not known. Researchers think a mix of genetic, immune and environmental factors sets off the abnormal immune response, but no single trigger has been identified, and it is not inherited in a predictable way. It affects men and women about equally and is most often diagnosed in middle age, usually in people who already have asthma. In some people, EGPA comes to light soon after a new asthma medicine is started. Current thinking is that this usually happens because steroid treatment is being reduced at the same time, uncovering inflammation the steroids had been holding back, rather than because the new medicine caused the disease.

How It's Diagnosed

No single test confirms EGPA, and there are no validated diagnostic criteria. A specialist puts together the history (especially asthma and sinus disease), the pattern of organ involvement, blood tests, imaging and, when possible, a biopsy. The most telling blood test is the eosinophil count. A count above 1,000 cells per microliter (sometimes reported as 1.0 x 10^9 per liter, or above about 10 percent of all white cells) in someone not taking steroids raises strong suspicion. Steroids lower the count quickly, so a count above about 500 can still be meaningful in someone already taking them. A test for ANCA (antineutrophil cytoplasmic antibodies, autoantibodies seen in several types of vasculitis) is positive in roughly a third to a half of people. A positive result supports the diagnosis and is linked to more nerve and kidney involvement, but a negative result does not rule EGPA out. Chest and sinus imaging such as CT (computed tomography) scans, urine and blood tests of kidney function, and tests of the heart and nerves show which organs are affected. A biopsy of skin, nerve, lung or other tissue can show eosinophils and inflamed vessels, though it is not always possible or conclusive. Doctors also rule out other causes of high eosinophils, such as parasitic infections, drug reactions, allergic lung conditions and blood disorders like hypereosinophilic syndrome.

Treatment Options

Treatment aims to switch off the inflammation, protect organs and keep the disease in remission with as little medicine as possible. The plan depends mostly on whether vital organs are threatened. Corticosteroids such as prednisone are the starting point for nearly everyone and usually work quickly. They are begun at a high dose and tapered over months. Long-term steroid use brings real harms, including serious infections, bone thinning and fractures, high blood pressure, diabetes and cataracts, so much of EGPA care is about bringing the dose down safely. Steroids should never be stopped suddenly or adjusted without the care team, because the body needs time to recover its own hormone production and the disease can flare. When the heart, nerves, kidneys, gut or lungs are seriously affected, treatment starts with high-dose steroids through a vein plus a stronger immune-suppressing drug: rituximab, an antibody infusion that removes the B cells that make antibodies, or cyclophosphamide, a powerful immunosuppressant. Rituximab is often preferred for ANCA-positive or relapsing disease and for people who may want children, since cyclophosphamide can affect fertility and raise long-term cancer and infection risk. Two biologic injections, mepolizumab (Nucala) and benralizumab (Fasenra), are approved by the US Food and Drug Administration (FDA) for adults with EGPA. Both block the interleukin-5 signal that eosinophils need, given as an injection under the skin every 4 weeks. In trials of people whose disease had relapsed or resisted treatment, they increased time in remission and let many people lower their steroid dose, though only about half reached full remission. In a head-to-head trial they worked about equally well, and more people stopped steroids entirely on benralizumab. These are commonly used for asthma-heavy or eosinophil-driven disease and to keep remission going. Older pills such as methotrexate, azathioprine or mycophenolate are other options for maintenance. Asthma and sinus disease usually also need their own inhaled and nasal treatment.

What to Expect

With proper treatment EGPA can usually be brought under control, but it is typically a long-term condition rather than a one-time illness. In a large North American study followed for about seven years, about half of people had at least one relapse, and only about one in eight managed to be off all treatment for more than two years. Many people stay on a low dose of steroids, a biologic, or both. The most common lasting problems are persistent asthma, nerve damage that leaves numbness or weakness in the hands or feet, and chronic sinus disease. Asthma or sinus symptoms can also worsen on their own without the vasculitis returning, which is why flares are assessed rather than assumed. Follow-up is regular and often shared among a lung specialist, rheumatologist and sometimes cardiology, neurology or ENT (ear, nose and throat) specialists. Visits typically include blood counts, urine tests and checks for heart, nerve and kidney involvement, along with care for the side effects of treatment: staying current on vaccines, protecting bone health, and watching blood sugar and blood pressure.

When to Seek Help

See a doctor if you have asthma that is new in adulthood or getting harder to control, together with sinus problems, unexplained fevers, weight loss, rashes or a high eosinophil count on a blood test, and ask whether a specialist assessment for EGPA makes sense. If you have EGPA, contact your care team promptly for new numbness, tingling or weakness in a hand or foot, blood in the urine or noticeably dark urine, new purple spots or skin sores, fever while on immune-suppressing treatment, or asthma that is suddenly much worse. These can signal a flare or a complication that needs treatment adjusted quickly. Get emergency care for chest pain, fainting, a racing or irregular heartbeat, sudden severe shortness of breath or coughing up blood, since EGPA can inflame the heart and lungs.

Questions to Ask Your Doctor

  1. 1.Which of my organs are affected, and is my disease considered severe or non-severe?
  2. 2.What is my ANCA result, and how does it change the treatment you recommend?
  3. 3.How will we lower my steroid dose over time, and is a biologic like mepolizumab or benralizumab right for me?
  4. 4.Which tests will we use to check my heart, nerves and kidneys, and how often?
  5. 5.How will we tell an asthma or sinus flare apart from the vasculitis coming back?

Last reviewed • Oct 2026

Educational content, not medical advice.